Literature DB >> 10708709

Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.

U Kintscher1, K Kappert, G Schmidt, G Doerr, M Grill, B Wollert-Wulf, M Graefe, E Fleck, K Graf.   

Abstract

human umbilical venous endothelial cells. 7E3 binding correlated with alphavbeta3-expression in all cell types. Integrin-mediated cell functions were analysed with adhesion and spreading assays on vitronectin. In human umbilical venous endothelial cells, these functions were mediated by alphavbeta3 and in human iliac arterial smooth muscle cells by alphavbeta5. In human umbilical venous smooth muscle cells, both vitronectin receptors were involved. Abciximab potently inhibited alphavbeta3-mediated cell adhesion and spreading. With tirofiban, no significant inhibition of vascular cell functions was observed. The present data demonstrate that vitronectin-cell interactions in vascular cells are mediated via two distinct integrin-receptors, alphavbeta3 and alphavbeta5. Abciximab, which solely inhibits alphavbeta3-mediated cell functions, may be particularly effective in human endothelium and in beta3-integrin expressing vascular smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10708709     DOI: 10.1016/s0014-2999(99)00912-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials.

Authors:  Ulf Bertram; Martin Moser; Karlheinz Peter; Helmut F Kuecherer; Raffi Bekeredjian; Andreas Straub; Thomas K Nordt; Christoph Bode; Johannes Ruef
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 2.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Authors:  Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-09-26       Impact factor: 2.300

Review 3.  Rationale for intracoronary administration of abciximab.

Authors:  Enrico Romagnoli; Francesco Burzotta; Carlo Trani; Giuseppe G L Biondi-Zoccai; Floriana Giannico; Filippo Crea
Journal:  J Thromb Thrombolysis       Date:  2007-02       Impact factor: 2.300

Review 4.  Integrin-based therapeutics: biological basis, clinical use and new drugs.

Authors:  Klaus Ley; Jesus Rivera-Nieves; William J Sandborn; Sanford Shattil
Journal:  Nat Rev Drug Discov       Date:  2016-01-29       Impact factor: 84.694

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.